三种定量免疫化学粪便隐血试验在结直肠癌筛查中的应用分析比较
栏目:行业动态 发布时间:2020-07-08
目前已建立了几种免疫化学粪便潜血试验(I-FOBT)优于结直肠癌筛查中基于愈创木脂的试验的优越性。本研究的目的是比较3种定量I-FOBT的分析性能。

背景:

目前已建立了几种免疫化学粪便潜血试验(I-FOBT)优于结直肠癌筛查中基于愈创木脂的试验的优越性。本研究的目的是比较3种定量I-FOBT的分析性能。


方法:

来自10名健康志愿者的粪便样本,最初为I-FOBT阴性,样本添加人血,用于比较不同储存温度((4°C,10°C,20°C和30°C)下测量的重现性和稳定性)和3个I-FOBT(新的Hemtube / Magstream HT,OC-Auto采样瓶3 / OC-Sensor DIANA和FOB Gold / SENTiFOB)的测试分析(1到10天)之前的持续时间。评估浓度范围为0至350μgHb/ g的粪便。


结果:

OC-Sensor的测量重现性优于Magstream,远远优于FOB Gold。对于所有测试,可变性主要与采样有关。在温度高于20°C的所有测试中,检测到的血红蛋白(Hb)水平显着降低。在20°C时,OC-Sensor的浓度损失不太重要(每日减少1.7%,而Magstream为7.4%,FOB Gold为7.8%)。在30°C时,使用OC-Sensor每日损失为8.6%,而在24小时后,使用FOB Gold检测到仅有30%的原始Hb,而使用Magstream检测到70%。对于后两种测试,在第5天未检测到Hb。


结论:

关于再现性和温度稳定性,OC-Sensor比Magstream表现更好,远远好于FOB Gold。


【参考文献】

1. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane syste-matic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008;103:1541–9.

 

2. Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsene D, Boutreux S, et al.Comparison of guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007;56:210–4.

 

3. Van Rossum LG, Van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, vanKrieken HH, et al. Random comparison of guaiac and immunochem- ical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008;135:82–90.

 

4. Hol L, Wilschut JA, van Ballegooijen M, van Vuuren AJ, van der Valk H,Reijerink JC, et al. Screening for colorectal cancer: random compar- ison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009;100:1103–10.

 

5. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, et al. Aquantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007;146:244–55.

 

6. Grazzini G, Visioli CB, Zorzi M, Ciatto S, Banovich F, Bonanomi AG,et al. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Br J Cancer 2009;100:259–65.

 

7. Guittet L, Bouvier V, Mariotte N, Vallee JP, Levillain R, Tichet J, et al.Performances of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples. Int J Cancer 2009;125:1127–33.

 

8. van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P,Jansen JB, et al. Cutoff value determines the performance of a semi- quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. Br J Cancer 2009;101:1274–81.

 

9. U.S. Preventive Services Task Force. Screening for colorectal cancer:U.S. preventive services task force recomm

 

10. Lieberman DA. Clinical practice. Screening for colorectal cancer. NEngl J Med 2009;361:1179–87.

 

11. van Rossum LG, van Rijn AF, van Oijen MG, Fockens P, Laheij RJ,Verbeek AL, et al. False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening. Int J Cancer 2009;125:746–50.

 

12. Grazzini G, Ventura L, Zappa M, Ciatto S, Confortini M, Rapi S, et al.Influence of seasonal variations in ambient temperatures on perfor- mance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from Florence district. Gut 2010;59:1511–5.

 

13. Australian Government, Department of Health and Aging. Nationalbowel cancer screening program: screening retest fact sheet.[accessed 2010 Sept 13]. Available from: www.cancerscreening. gov.au/internet/screening/publishing.nsf/content/bw-retest

 

14. Rozen P, Waked A, Vilkin A, Levi Z, Niv Y. Evaluation of a desk topinstrument for the automated development and immunochemical quantification of fecal occult blood. Med Sci Monit 2006;12:MT27–32.

 

15. Ciatto S, Martinelli F, Castiglione G, Mantellini P, Rubeca T, GrazziniG, et al. Association of FOBT-assessed faecal Hb content with colonic lesions detected in the florence screening programme. Br J Cancer 2007;96:218–21

 

16. NHS Evaluation report. Immunochemical faecal occult blood tests;2009 Nov. Report No.: CEP09042.

 

17. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. Acomparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005;129:422–8.

 

18. Guittet L, Bouvier V, Mariotte N, Vallee JP, Levillain R, Tichet J, et al.Comparison of a guaiac and an immunochemical fecal occult blood test for the detection of colonic lesions according to lesion type and location. Br J Cancer 2009;100:1230–5.

上一篇: 没有了